Skip to main content

Month: September 2020

Aemetis Starts Production of Branded High-Grade Alcohol Sanitizer Products

Aemetis Health Products Brand to be Sold on Amazon and Through Retail ChainsCUPERTINO, CA, Sept. 21, 2020 (GLOBE NEWSWIRE) — via NewMediaWire —Aemetis, Inc. (NASDAQ: AMTX) (“Aemetis”), an advanced renewable fuels and biochemicals company, today announced commencement of contracted production of hand sanitizer under its branded Aemetis Health Products label for sales to government, businesses and academic customers, as well as directly to consumers via the Amazon Marketplace.“Following through on our plan to address the ongoing demand for sanitizer products and having received FDA label registration and other approvals, we have commenced contracted production of sanitizer products under our Aemetis Health Products subsidiary brand name,” said Eric McAfee, Chairman and CEO of Aemetis, Inc. “Aemetis’ 65 million gallon per year...

Continue reading

Reminder: ViralClear to Host Conference Call and Webcast on September 22, 2020 to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19

Westport, CT, Sept. 21, 2020 (GLOBE NEWSWIRE) —Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Merimepodib in Combination with Remdesivir in Hospitalized Adults with COVID-19 Who Require Non-Invasive Ventilation/High Flow Oxygen Devices or Supplemental OxygenPresentation to include webcastBioSig Technologies, Inc.’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced that it will host a call and webcast to discuss its Phase 2 clinical trial.  The study is a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of merimepodib (MMPD) in combination with remdesivir for hospitalized adult patients who have confirmed infection with SARS-CoV-2 and require non-invasive ventilation/high flow oxygen devices or supplemental oxygen...

Continue reading

Consolidated Communications Partners with Pax8, the Leader in Cloud Distribution, to Enhance its Cloud Services

MATTOON, Ill., Sept. 21, 2020 (GLOBE NEWSWIRE) — Consolidated Communications (NASDAQ: CNSL), a leading broadband and business communications provider, today announced it has partnered with Pax8, the leader in cloud distribution, to provide business customers with an enhanced suite of cloud services, including: next generation productivity, backup, security, data management and disaster recovery solutions.The partnership will simplify and streamline the order and fulfillment process for business customers, ultimately shortening the provisioning timeline. It will enable Consolidated Communications to more effectively deliver cloud services to the marketplace.“This strategic partnership will improve the buying and installation experience for our business customers through the delivery of an enhanced portfolio of cloud services at competitive...

Continue reading

Verizon says ‘NO’ to more than 7 billion robocalls and counting

BASKING RIDGE, N.J., Sept. 21, 2020 (GLOBE NEWSWIRE) — Verizon continues to be an industry leader in protecting over 75 million customers from pesky robocalls, with over 7 billion calls and counting. And for the 10th consecutive month, there’s an industry-wide decline in the volume and frequency of robocalls that customers receive. This is due, in part, to Verizon’s continued efforts on behalf of customers within the network and application levels, including the rollout of new network technology in iOS 14 that automatically sends robocalls to voicemails for Verizon iOS customers. We’ve got your back. With the introduction of a new setting in iOS 14 to Silence Junk Callers, Verizon is able to provide further protections for iOS customers by auto-blocking potential fraud and spam calls and sending them directly to voicemail. This...

Continue reading

Claritas HealthTech Pte. Ltd. to enter the North American market via CAD$5M Licensing Agreement and Reverse Takeover of TSXV listed tech company

SINGAPORE, Sept. 21, 2020 (GLOBE NEWSWIRE) — Singapore-based Claritas HealthTech Pte. Ltd. (“Claritas”) and Labrador Technologies Inc. (“Labrador”) have entered into an exclusive arm’s length software license purchase agreement dated June 28, 2020.Pursuant to the terms of the Agreement, Labrador will issue sufficient shares such that the Proposed Transaction will constitute a Reverse Takeover (“RTO”) of Labrador under the policies of the TSX Venture Exchange (the “Exchange” or the “TSXV”). Upon the closing of the Proposed Transaction, it is expected that Labrador will continue to be a Technology Issuer on the TSXV and will be renamed as Claritas HealthTech Inc.“With our iRAD platform successfully tested and continuing to be deployed across Asia, the next natural step is for Claritas to establish a presence in North America on account...

Continue reading

Shaw Business Launches SmartTarget to Help Business Owners Build Customer Relationships and Increase In-Store Traffic

CALGARY, Alberta, Sept. 21, 2020 (GLOBE NEWSWIRE) — Shaw Communications Inc. today announced the launch of SmartTarget for Shaw Business customers — an all-in-one digital marketing and advanced insights solution that leverages the combined power of Shaw’s SmartWiFi service and new technology to give business owners a deeper understanding of who their customers are, what they want, and the ability to easily take action to drive traffic to their brick-and-mortar locations, boost revenue and create repeat customers.With SmartTarget available as an add-on service to Shaw’s SmartWiFi, business owners get detailed customer demographic insights when visitors join its guest WiFi network. Once customers have given their consent, business owners use SmartTarget’s automated campaign tools and leverage these insights to create targeted emails,...

Continue reading

Organisational changes and ESG investor seminar

Oslo, 21 September 2020: Yara makes organisational changes effective 1 October, and announces an ESG investor seminar to be held 3 December 2020. “The organisational changes we make today support Yara’s ongoing transition towards providing sustainable solutions for the global food system, and we look forward to presenting the next steps in our transition during our ESG investor seminar later this year,” said Svein Tore Holsether, President & CEO.

Continue reading

Avid Breaks New Ground by Enabling Content Creators to Seamlessly Collaborate with Adobe Premiere Pro Editors

BURLINGTON, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) — Avid® (NASDAQ: AVID) is breaking new ground by enabling content creators and video editors who use Adobe® Premiere® Pro to collaborate seamlessly in Avid-based production environments. Avid’s upcoming release of its MediaCentral®| Panel for Adobe Premiere Pro–a lightweight software plugin that enables Premiere Pro editors to connect with post-production workflows for news and sports—offers the full advantage of Avid storage, asset management and team collaboration. This integration enables editors to browse, search, access and edit content and metadata without ever leaving Adobe Premiere Pro.In addition, Avid will be hosting the Breaking the Content Silo Webinar for the creative community, which will highlight the new integrated workflow, on Thursday, Sept. 24 at 2 p.m. Eastern/11...

Continue reading

Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020

Media ReleaseData featured in late-breaking proffered paper oral presentation Biologics license application submission planned to support accelerated approval pathway with the FDAGenmab A/S (Nasdaq: GMAB) and Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. Patients had previously received a doublet chemotherapy and, if eligible, bevacizumab as first-line therapy. Results from the trial showed a 24 percent confirmed objective response rate (ORR) by independent central review with a median duration of response (DOR) of 8.3 months. The most common treatment-related adverse...

Continue reading

CSX Supports Rail Safety Week to Promote Public Safety near Railroad Tracks

JACKSONVILLE, Fla., Sept. 21, 2020 (GLOBE NEWSWIRE) — CSX Corp. (NASDAQ: CSX) is once again teaming up with Operation Lifesaver, Inc. (OLI) to increase public safety near railroad tracks during the fourth annual Rail Safety Week. Rail Safety Week is a unique, collaborative, nationwide initiative that brings together freight and passenger railroads, regulators, law enforcement and non-profit organizations to educate in effort to save lives. To be mindful of COVID-19 risks, the Rail Safety Week public safety campaign will be conducted virtually this year. CSX will leverage its digital platforms and social media to educate communities across its 23 state network of the inherent dangers of unsafe behavior near railroad tracks.   “At CSX, we are committed to the safety of our employees and communities, and our participation in Rail Safety...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.